KAT6B
KAT6B (Histone acetyltransferase KAT6B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Nasopharyngeal carcinoma, Prostate cancer and 4 more.
Overview
Histone acetyltransferase which may be involved in both positive and negative regulation of transcription. Required for RUNX2-dependent transcriptional activation. May be involved in cerebral cortex development.
Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes literature 0.89, animal model 0.28, genetic association 0.00, somatic mutation 0.87). IntOGen calls it a driver in 5 cohorts (1 activating, 4 loss-of-function), covering Invasive Breast Carcinoma, Low-Grade Glioma, NOS, Medulloblastoma, Nasopharyngeal Carcinoma, Prostate Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · KAT6B (Histone acetyltransferase KAT6B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Nasopharyngeal carcinoma, Prostate cancer and 4 more.
- 1 · What it is
KAT6B (Histone acetyltransferase KAT6B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Nasopharyngeal carcinoma, Prostate cancer and 4 more.
- 2 · What goes wrong in cancer
Histone acetyltransferase which may be involved in both positive and negative regulation of transcription. Required for RUNX2-dependent transcriptional activation.
- 3 · How drugs use it
No product in this corpus aims at KAT6B yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:17582 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8WYB5 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000156650 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: colorectal cancer 0.51, melanoma 0.51, skin cancer 0.55, breast cancer 0.58 (GraphQL API, CC0)); IntOGen KAT6B (driver in 5 cohorts (Act 1, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Histone acetyltransferase which may be involved in both positive and negative regulation of transcription. Required for RUNX2-dependent transcriptional activation. May be involved in cerebral cortex development. Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. Location: Nucleus (UniProt). Locus 10q22.2 (HGNC).
- Breast cancer: Open Targets association 0.58 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.51 with colorectal cancer (MONDO_0005575)
- Medulloblastoma: IntOGen driver in 1 cohort (MBL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Low-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"KAT6B" OR ABSTRACT:"KAT6B" OR TITLE:"lysine acetyltransferase 6B" OR ABSTRACT:"lysine acetyltransferase 6B" OR TITLE:"Histone acetyltransferase KAT6B" OR ABSTRACT:"Histone acetyltransferase KAT6B" OR TITLE:"querkopf" OR ABSTRACT:"querkopf" OR TITLE:"qkf" OR ABSTRACT:"qkf" OR TITLE:"Morf" OR ABSTRACT:"Morf") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KAT6B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZNF331
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Melanoma.
- TargetWAS
Shares Medulloblastoma, Skin cancer (all types), IntOGen, Melanoma.
- TargetFOXO3
Shares Medulloblastoma, Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetTRIM33
Shares Medulloblastoma, Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetCYLD
Shares Nasopharyngeal carcinoma, Breast cancer (all types), IntOGen, Prostate cancer.
- TargetSPEN
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetHIP1
Shares Medulloblastoma, Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetMYH11
Shares Nasopharyngeal carcinoma, Breast cancer (all types), IntOGen, Melanoma.